Genticel’s Phase II study with ProCervix passes the halfway mark for patient recruitment

Genticel, a French biotechnology company and developer of therapeutic vaccines, has announced that the enrollment of the Phase II RHEIA-VAC study has reached the halfway mark of its recruitment target.

The study is on track with Genticel’s initial projections. All of the 39 investigation sites across seven European countries (Belgium, Finland, France, Germany, the Netherlands, Spain and the UK) are fully operational. 

Furthermore, the Data and Safety Monitoring Board (DSMB), an independent committee of experts who monitor safety data every 6 months during the study, met as scheduled on 1 July and recommended pursuing the RHEIA-VAC study as planned. 

Benedikt Timmerman, the founder and CEO of Genticel, said: “We are very satisfied with the progress of the study and with the involvement of our investigators, whose motivation has largely contributed to this progress. At this rate, we shall have completed all of our patient recruitment as projected, by the first semester of 2015.”